Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.
Alzheimer's disease
biomarker
dementia
mild cognitive impairment
neurofilament
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
18
09
2023
received:
15
06
2023
accepted:
21
09
2023
pubmed:
5
10
2023
medline:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (area under the curve [AUC] 0.82). We identified cut-off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (progressive SCD [p-SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p-MCI]). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p-MCI (3.52 ± 4.06 pg/mL) compared to non-progressive SCD (0.81 ± 1.25 pg/mL) and non-progressive MCI (-0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954). Plasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
METHODS
METHODS
This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and
RESULTS
RESULTS
At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (area under the curve [AUC] 0.82). We identified cut-off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (progressive SCD [p-SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p-MCI]). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p-MCI (3.52 ± 4.06 pg/mL) compared to non-progressive SCD (0.81 ± 1.25 pg/mL) and non-progressive MCI (-0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954).
CONCLUSION
CONCLUSIONS
Plasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16089Subventions
Organisme : Ministero della Salute
Organisme : Regione Toscana
Informations de copyright
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844-852.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimer's Dement. 2023;9:e12385.
Margolis SA, Kelly DA, Daiello LA, et al. Anticholinergic/sedative drug burden and subjective cognitive decline in older adults at risk of Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2021;76:1037-1043.
Gafson AR, Barthélemy NR, Bomont P, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020;143:1975-1998.
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870-881.
Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595-599.
Bangen KJ, Thomas KR, Weigand AJ, et al. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI. Alzheimers Dement. 2021;17:1756-1762.
Mattsson N, Andreasson U, Zetterberg H, Blennow K. For the Alzheimer's disease neuroimaging initiative. Association of Plasma Neurofilament Light with Neurodegeneration in patients with Alzheimer disease. JAMA Neurology. 2017;74:557-566.
Götze K, Vrillon A, Bouaziz-Amar E, et al. Plasma neurofilament light chain in memory clinic practice: evidence from a real-life study. Neurobiol Dis. 2023;176:105937.
Sarto J, Ruiz-García R, Guillén N, et al. Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort. Neurology. 2023;100:e860-e873.
Planche V, Bouteloup V, Pellegrin I, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100:e473-e484.
Silva-Spínola A, Lima M, Leitão MJ, et al. Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia. Eur J Neurol. 2023;30:1565-1573.
Tosun D, Veitch D, Aisen P, et al. Detection of β-amyloid positivity in Alzheimer's disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021;3:fcab008.
Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2022;18:1141-1154.
Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25:277-283.
de Wolf F, Ghanbari M, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220-1232.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
Mazzeo S, Lassi M, Padiglioni S, et al. PRedicting the EVolution of SubjectIvE cognitive decline to Alzheimer's disease with machine learning: the PREVIEW study protocol. BMC Neurol. 2023;23:300.
Alcolea D, Pegueroles J, Muñoz L, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Ann Clin Transl Neurol. 2019;6:1815-1824.
Bessi V, Balestrini J, Bagnoli S, et al. Influence of ApoE genotype and clock T3111C interaction with cardiovascular risk factors on the progression to Alzheimer's disease in subjective cognitive decline and mild cognitive impairment patients. J Pers Med. 2020;10:45.
Mazzeo S, Polito C, Padiglioni S, et al. Linguistic profiles, brain metabolic patterns and rates of amyloid-β biomarker positivity in patients with mixed primary progressive aphasia. Neurobiol Aging. 2020;96:155-164.
Jack CR, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539-547.
Simrén J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. Brain Commun. 2022;4:fcac174.
Giacomucci G, Mazzeo S, Bagnoli S, et al. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269:4270-4280.
Khalil M, Pirpamer L, Hofer E, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11:812.
Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557-566.
Benussi A, Cantoni V, Rivolta J, et al. Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration. Alzheimers Res Ther. 2022;14:155.
Benedet AL, Leuzy A, Pascoal TA, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain. 2020;143:3793-3804.
Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline. Neurology. 2020;95:e46-e58.
Bessi V, Mazzeo S, Padiglioni S, et al. From subjective cognitive decline to Alzheimer's disease: the predictive role of neuropsychological assessment, personality traits, and cognitive reserve. A 7-year follow-up study. J Alzheimers Dis. 2018;63:1523-1535.
Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130:439-451.